|
[1] SUN Y, ZHOU J, WANG L, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J]. Hepatology, 2017, 65 (5) :1438-1450.
|
|
[2]DUCHATELLE V, MARCELLIN P, GIOSTRA E, et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to18 months later in patients with chronic hepatitis C:Quantitative assessment by a morphometric method[J]. J Hepatol, 1998, 29 (1) :20-28.
|
|
[3]GOODMAN ZD, STODDARD AM, BONKOVSKY HL, et al. Fibrosis progression in chronic hepatitis C:Morphometric image analysis in the HALT-C trial[J]. Hepatology, 2009, 50 (6) :1738-1749.
|
|
[4]ARIMA M, TERAO H, KASHIMA K, et al. Regression of liver fibrosis in cases of chronic liver disease type C:Quantitative evaluation by using computed image analysis[J]. Intern Med, 2004, 43 (10) :902-910.
|
|
[5]SUN Y, ZHOU J, WU X, et al. Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak"stable"patients on anti-HBV therapy[J]. Sci Rep, 2018, 8 (1) :2989.
|
|
[6] WANLESS IR, NAKASHIMA E, SHERMAN M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis[J]. Arch Pathol Lab Med, 2000, 124 (11) :1599-1607.
|
|
[7]BEDOSSA P. Reversibility of hepatitis B virus cirrhosis after therapy:Who and why?[J]. Liver Int, 2015, 35 (Suppl 1) :78-81.
|
|
[8] CHON YE, PARK JY, MYOUNG SM, et al. Improvement of liver fibrosis after long-term antiviral therapy assessed by fibroscan in chronic hepatitis B patients with advanced fibrosis[J]. Am J Gastroenterol, 2017, 112 (6) :882-891.
|
|
[9]FACCIORUSSO A, DEL PRETE V, TURCO A, et al. Longterm liver stiffness assessment in hepatitis C virus patients undergoing antiviral therapy:Results from a 5-year cohort study[J]. J Gastroenterol Hepatol, 2018, 33 (4) :942-949.
|
|
[10]LIANG X, XIE Q, TAN D, et al. Interpretation of liver stiffness measurement-based approach for the monitoring of hepatitis B patients with antiviral therapy:A 2-year prospective study[J]. J Viral Hepat, 2018, 25 (3) :296-305.
|
|
[11]DONG XQ, WU Z, LI J, et al. Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B:A 78-week prospective study[J]. J Gastroenterol Hepatol, 2018.[Epub ahead of print]
|
|
[12]IMAJO K, KESSOKU T, HONDA Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography[J]. Gastroenterology, 2016, 150 (3) :626-637.e7.
|
|
[13]TAPPER EB, LOOMBA R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD[J]. Nat Rev Gastroenterol Hepatol, 2018, 15 (5) :274-282.
|
|
[14]JAYAKUMAR S, MIDDLETON MS, LAWITZ EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis:Analysis of data from a phase II trial of selonsertib[J]. J Hepatol, 2018.[Epub ahead of print]
|
|
[15]VILAR-GOMEZ E, CHALASANI N. Non-invasive assessment of non-alcoholic fatty liver disease:Clinical prediction rules and blood-based biomarkers[J]. J Hepatol, 2018, 68 (2) :305-315.
|
|
[16]KIM BK, KIM DY, PARK JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients[J]. Liver Int, 2010, 30 (4) :546-553.
|
|
[17]LIN ZH, XIN YN, DONG QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis:An updated meta-analysis[J]. Hepatology, 2011, 53 (3) :726-736.
|
|
[18]KIM WR, BERG T, ASSELAH T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients[J]. J Hepatol, 2016, 64 (4) :773-780.
|
|
[19]XU H, KONG W, LIU L, et al. Accuracy of M2BPGi, compared with Fibro Scan, in analysis of liver fibrosis in patients with hepatitis C[J]. BMC Gastroenterol, 2017, 17 (1) :62.
|
|
[20]ZOU X, ZHU MY, YU DM, et al. Serum WFA+-M2BP levels for evaluation of early stages of liver fibrosis in patients with chronic hepatitis B virus infection[J]. Liver Int, 2017, 37 (1) :35-44.
|
|
[21]SHIRABE K, BEKKI Y, GANTUMUR D, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis:More than a biomarker of liver fibrosis[J]. J Gastroenterol, 2018, 53 (7) :819-826.
|
|
[22]HUI CK, LEUNG N, SHEK WH, et al. Changes in liver histology as a"surrogate"end point of antiviral therapy for chronic HBV can predict progression to liver complications[J]. J Clin Gastroenterol, 2008, 42 (5) :533-538.
|
|
[23]MALLET V, GILGENKRANTZ H, SERPAGGI J, et al. Brief communication:The relationship of regression of cirrhosis to outcome in chronic hepatitis C[J]. Ann Intern Med, 2008, 149 (6) :399-403.
|
|
[24]PAPATHEODORIDIS GV, IDILMAN R, DALEKOS GN, et al.The risk of hepatocellular carcinoma decreases after the first 5years of entecavir or tenofovir in caucasians with chronic hepatitis B[J]. Hepatology, 2017, 66 (5) :1444-1453.
|
|
[25]KIM MN, KIM SU, KIM BK, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis[J]. Hepatology, 2015, 61 (6) :1851-1859.
|
|
[26]KIM BS, SEO YS, KIM YS, et al. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis[J]. J Gastroenterol Hepatol, 2018, 33 (2) :503-510.
|
|
[27]WU S, KONG Y, PIAO H, et al. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis[J]. Liver Int, 2018, 38 (6) :1045-1054.
|
|
[28]SCHWABL P, HAMBRUCH E, SEELAND BA, et al. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction[J]. J Hepatol, 2017, 66 (4) :724-733.
|
|
[29]RATZIU V, HARRISON SA, FRANCQUE S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptoralpha and-delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology, 2016, 150 (5) :1147-1159, e5.
|
|
[30]NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT) :A multicentre, randomised, placebo-controlled trial[J]. Lancet, 2015, 385 (9972) :956-965.
|
|
[31]IKENAGA N, PENG ZW, VAID KA, et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal[J]. Gut, 2017, 66 (9) :1697-1708.
|
|
[32]HARRISON SA, ABDELMALEK MF, CALDWELL S, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis[J]. Gastroenterology, 2018, 155 (4) :1140-1153.
|
|
[33]FRIEDMAN SL, RATZIU V, HARRISON SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology, 2018, 67 (5) :1754-1767.
|
|
[34]HARRISON SA, MARRI SR, CHALASANI N, et al. Randomised clinical study:GR-MD-02, a galectin-3 inhibitor, vs.placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis[J]. Aliment Pharmacol Ther, 2016, 44 (11-12) :1183-1198.
|
|
[35]LOOMBA R, LAWITZ E, MANTRY PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis:A randomized, phase 2 trial[J]. Hepatology, 2017.[Epub ahead of print]
|
|
[36]MOHANTY A, TATE JP, GARCIA-TSAO G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis[J].Gastroenterology, 2016, 150 (2) :430-440. e1.
|
|
[37]KAMAL S, KHAN MA, SETH A, et al. Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease:A systematic review and Meta-analysis[J]. Am J Gastroenterol, 2017, 112 (10) :1495-1505.
|
DownLoad: